Remedy Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: New York NY United States (2004)
Status: Acquired by Biogen-IDEC (2017)

Organization Overview

First Clinical Trial
2010
NCT01132703
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

glyburide (micronase) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anthrax (Phase 2)

Brain Edema (Phase 3)

Brain Injuries (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Edema (Phase 3)

Gas Gangrene (Phase 2)

Infarction (Phase 3)

Ischemia (Phase 2)

Stroke (Phase 3)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 1